Pros | ![]() Among most bought funds within the category. ![]() Larger AUM within category. ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() 5Y returns in the top 25% of the category. ![]() 3Y returns in the top 25% of the category. ![]() Larger AUM within category. | ||
Cons | ![]() 5Y returns in the bottom 25% of the category. | - |
INDMoney rank | 5/8 | 2/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 12 Years | 6 Years | ||
Fund Size | 8352 Cr | 5508 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.89% | 1.06% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 40 | 41 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (12.57%) Divi's Laboratories Ltd (9.49%) Lupin Ltd (5.82%) Cipla Ltd (5.62%) Dr Reddy's Laboratories Ltd (5.49%) | Sun Pharmaceuticals Industries Ltd (12.66%) Dr Reddy's Laboratories Ltd (9.66%) Divi's Laboratories Ltd (9.03%) Cipla Ltd (7.85%) Aurobindo Pharma Ltd (6.34%) | ||
No of Sectors | 1 | 3 | ||
Top 3 Sectors | Health (100%) | Health (94.88%) Basic Materials (3.81%) Financial Services (1.31%) | ||
Equity % | 98.58% | 96.99% | ||
Debt % | - | - | ||
P/E | 36.85 | 30.46 | ||
P/B | 5.96 | 4.13 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 3.57% | 3.58% | ||
3-Month Return | 7.57% | 8.65% | ||
6-Month Return | -0.97% | -0.35% | ||
1-Year Return | 16.87% | 22.95% | ||
3-Year Return | 26.64% | 31.17% | ||
5-Year Return | 23.42% | 25.85% |
Sharpe | 1.26 | 1.43 | ||
Alpha | 1.03 | 3.56 | ||
Beta | 0.9 | 0.94 | ||
Standard Deviation | 14.76 | 15.37 | ||
Information Ratio | -0.25 | 1.04 |
Description | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Sailesh Raj Bhan,Kinjal Desai | Dharmesh Kakkad |